Pa-Thai Yenchitsomanus is an expert in Biochemistry at Siriraj Hospital (Thailand). As of October 2026, ScienceLeadR ranks Pa-Thai Yenchitsomanus in the top 1% of experts in Thailand for Renal Tubular Transport, Inborn Errors. Pa-Thai Yenchitsomanus has authored 250 publications, the most recent in 2026. SLR score: 777 (community average: 125). How the SLR is computed.

LeadR Profile

Pa-Thai Yenchitsomanus Siriraj Hospital Thailand
777 ScienceLeadR Reputation 777
Network Map

Biochemistry

Subspecialties: Pharmacy - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1996 - 2026

Source: PubMed

Mahidol University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 250

Citations

Citations: 6 384 1st author: 5 Last author: 106 Unique author: 2


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Triple-costimulatory GD2-CAR T cells incorporating CD28, 4-1BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models.
PMID 42679446 — cytokines, cells, drug therapy, research, car-t cell
Biomed Pharmacother20261
Dual bispecific protein engager-armed T cells targeting BCMA and B7-H3 overcome antigen heterogeneity in multiple myeloma.
PMID 42497585 — cells, neoplasms, drug therapy, immunotherapy, multiple myeloma, research, therapeutics
Biomed Pharmacother20260
HLA class I-specific nucleolin peptides induce therapeutic T cells in triple-negative breast cancer patients.
PMID 42524378 — cells, triple negative breast neoplasms, breast neoplasms, biological science disciplines, neoplasms, immunotherapy, breast, alleles, therapeutics
Int J Biol Sci20260
Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.
PMID 42407326 — cells, carcinoma, hepatocellular, neoplasms, drug therapy, liver, research, car-t cell
Biomed Pharmacother20260
Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids.
PMID 42363170 — cells, neoplasms, immunotherapy, organoids, therapeutics, colorectal neoplasms, car-t cell
BMC Med20260

LeadR Networks

Main global connection map